Dr. Reidy-Lagunes on FDA Approval of Telotristat Ethyl for Carcinoid Syndrome

Diane Reidy-Lagunes, MD
Published: Tuesday, Feb 28, 2017



Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).


Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Understanding Carcinoid Syndrome Diarrhea From Diagnosis to TreatmentJun 29, 20191.0
Publication Bottom Border
Border Publication
x